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Background: Potentially inappropriate medications (PIMs) should be avoided by the aged popula-
tion. The aim of this study was to assess the prevalence of PIMs among Lebanese aged outpatients 
using Beers criteria of 2012. The secondary objectives were to identify the correlates of the PIMs 
use and to compare the PIMs prevalence rates as per Beers criteria of 2003 and 2012.
Methods: This cross-sectional observational study was conducted among aged outpatients 
of different accredited community pharmacies across Lebanon. Data were collected through a 
validated questionnaire. The Beers criteria of 2012 were used to evaluate PIMs. The associa-
tion between PIMs used and independent variables were analyzed by logistic regression. The 
differences between PIMs use according to Beers criteria 2003 and 2012 were calculated using 
chi-squared and McNemar’s tests.
Results: A total of 248 outpatients were analyzed. We identified 112 (45.2%) out of 248 patients 
taking PIMs. The leading classes of medications identified to cause PIMs were those acting on 
the central nervous system (71.4%). The factors associated with PIMs use were age, osteoporosis, 
Alzheimer/dementia, diabetes, and alcohol consumption. PIMs use increased significantly between 
Beers criteria 2003 and 2012 (Chi-squared test, P,0.001; McNemar’s test, P,0.001).
Conclusion: Our study showed a high prevalence of PIMs use in Lebanon, which is associated 
with various correlates. Education of health care providers and medication review should be 
considered to improve medication safety of older adults.
Keywords: Beers criteria, aged, inappropriate drug prescriptions, outpatients, potentially 
inappropriate medication
Introduction
The aged population accounts for a significant part of the population in many countries 
of the world. Between 2000 and 2050, the proportion of the world’s population aged 
more than 60 years will double from approximately 11% to 22%.1 In Lebanon, the 
proportion of the aged population has been increasing since 1990, where it stood at 
5.2% to reach 9.2% in 2013, and is expected to reach 21% in 2050.2,3 The presence 
of many comorbidities, polypharmacy, physiological changes, and socioeconomic 
status constitute risk factors for the occurence of adverse drug events (ADEs) in this 
high risk population.4,5
Furthermore, while polypharmacy is a common phenomenon in aged populations 
because of multimorbidity, it is associated with inappropriate drug use and drug inter-
actions leading to an increased risk of adverse drug reactions/events and indices of 
morbidity and mortality, especially among the very old.6–8 Potentially inappropriate 
medication (PIM) is defined as: 
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A drug in which the risk of an adverse event outweighs its 
clinical benefit, particularly when there is a safer or more 
effective alternate therapy for the same condition.9
Several criteria have been designed for the identification 
of PIMs, including the Beers criteria. The Beers criteria are 
guidelines based on expert consensus developed through 
an extensive literature review by recognized experts in 
geriatric care, clinical pharmacology, and psychopharma-
cology in the USA. The aim of these guidelines is to assist 
health care professionals improve the safety of prescribing 
medications for older adults by reducing the risk associ-
ated with polypharmacy, drug interactions, and adverse 
drug reactions.10 Beers criteria have undergone a major 
reformation in 201210 by the American Geriatrics Society 
based on evidence-based recommendations as compared 
with the previous version of 2003.11
The use of PIMs has been studied in various settings, 
including the outpatient,12–16 hospital,17,18 and the care home 
setting.19–21 Identifying PIMs is the first step in the process 
of minimizing the pharmacotherapy-related hazards in this 
vulnerable population.
In this study, our main goal was to assess the prevalence 
of PIMs among Lebanese aged outpatients using Beers 
criteria of 2012.10 We also intended to investigate whether 
demographic characteristics, alcohol consumption, smoking 
habits, and comorbidities are associated with the use of PIMs. 
Finally, we aimed to compare the prevalence of PIMs in 
Lebanon based on Beers criteria of 2012 versus 2003. Data 
on the 2003 PIMs prevalence were based on a previous study 
conducted on Lebanese aged outpatients in the same settings 
as our study with a different database.22
Methods
study design and population
From April to August 2012, a national, multicenter, obser-
vational, cross-sectional questionnaire-based study was con-
ducted in a convenient sample of Lebanese aged outpatients 
of different accredited community pharmacies located in 
different areas of Lebanon. Patients who met the eligibility 
criteria were enrolled in the study. Eligible participants for 
this study were Lebanese outpatients aged $65 years, filling 
their prescriptions, with at least one prescription drug for 
their own use in community pharmacy settings.
Data collection
Each pharmacy was asked to select 16 aged patients to enroll 
in the study. Each day, the first eligible patient who came in 
the pharmacy was invited to complete the questionnaire on 
site. This face-to-face method relied on soliciting the patient’s 
answers to written questions by survey with direct assistance 
of the interviewee.
Patients were interviewed in Lebanese Arabic by 
phar macists, who were well trained to conduct standardized 
questionnaires. An in-charge pharmacist was available for 
conducting regular quality control checks on the process. For 
ethical purposes, the names of the patients were undisclosed, 
and patients were referred by identification numbers.
The updated Beers criteria of 2012 were used to construct 
the questionnaire and detect questions relevant to the analy-
sis.10 The final version of the questionnaire was pretested and 
written in English. It included the following: age and sex of 
the patient and location of the pharmacy. It also focused on 
the list of medications received by the patients, including 
drug name, dose, route, and frequency of administration. The 
date of the treatment initiation and planned duration were 
also requested. Data about over-the-counter medicines and 
multivitamins were reported. Comorbidities of the patients 
were also reported. A list of the relevant health conditions, 
as reported in the Beers criteria of 2012, was provided to the 
interviewer to check if consistent with the patient medical 
history. Any other relevant information was also documented. 
Reported comorbidities were based on a previous diagnosis 
by a physician.
PIM criteria
Courses of therapy were assessed and classified as either 
appropriate or inappropriate. Beers criteria of 2012 were used 
as the source to identify PIMs among the aged.10 Beers PIMs 
were further classified into three categories: 1) PIMs and 
classes of medications to avoid in older adults, 2) PIMs and 
classes of medications to avoid in older adults with certain 
diseases and syndromes that the drugs can exacerbate, and 
3) medications to be used with caution in older adults.
statistical analysis
Records for aged patients with incomplete, insufficient, or 
conflicting data were excluded. Sample characteristics were 
summarized using the mean and the standard deviation for 
age and frequency distributions for all other variables such 
as age groups, sex, and smoking habits. Comorbidities 
were summarized using frequency distribution and grouped 
according to the World Health Organization International 
Classification of Diseases (ICD)-10 subgroups.23 Those were 
compared between males and females using the chi-squared 
test or Fisher’s exact test when expected cell counts fell 
below five.
The prevalence of PIMs was computed based on Beers cri-
teria of 2012. Moreover, the prevalence of PIMs and classes 
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to avoid in older adults with certain diseases and syndromes 
that the drugs can exacerbate and the prevalence of PIMs to 
be used with caution in older adults were computed.
Logistic regression was used to assess the potential 
relationship between this main outcome of PIMs use and 
demographic variables and comorbidities. The Hosmer and 
Lemeshow goodness-of-fit test was used for the logistic 
regression model in order to assess model fit. Variables 
showing a P-value of 0.25 or less at the bivariate level were 
included in the multivariable model. The final multivari-
able model included variables that were significant or had 
confounding effect on other variables.
In order to assess changes in the prevalence of PIMs 
over years, the prevalence of PIMs as assessed in this 
study with Beers criteria of 2012 and its counterpart as 
reported by Saab et al according to Beers criteria of 200322 
were compared using the chi-squared test. In addition, the 
prevalence in Saab et al was compared with the prevalence 
of PIMs from this study assuming the same Beers criteria 
of 2003 were used. Finally, we compared within our study, 
the prevalence of PIMs according to Beers criteria of 2003 
and 2012 using McNemar’s test. The main key was to 
verify whether the increase in the prevalence of PIMs in 
the present study as compared with the Saab et al study is 
strictly due to the intake of medications that were recently 
considered inappropriate and accordingly added to the 2012 
list of Beers criteria.
Significance level was set at 5%. The statistical analysis 
was carried out using IBM-SPSS version 21 software 
for Windows Release (Released 2012 IBM Corporation, 
Armonk, NY, USA).
ethical consideration
The study was approved by the Lebanese American Univer-
sity’s Institutional Review Board. The purpose of the study 
was elucidated and verbal consent was obtained before the 
participants were interviewed, respecting their autonomy 
and anonymity.
Results
recruitment of the patients
Over 5 months, a total of 253 aged patients’ profiles in 16 
pharmacies across Lebanon were reviewed in this study, of 
which 248 were eligible for the statistical analysis. Five par-
ticipants were excluded from the final analysis for incomplete 
data provision, mainly age.
Demographic characteristics of the 
patients
The final analyzed sample ranged in age between 65 years 
and 98 years with an average of 70.9±5.0 years and with 
a male to female ratio of 1.56 (95% confidence interval 
[CI] =0.94–2.59). Cigarette smoking and alcohol consump-
tion were reported by 29.8% and 25.0% of the participants, 
respectively (Table 1).
Comorbidity characteristics of patients
Diseases of the circulatory system as well as endocrine, 
nutritional, and metabolic disorders were the most reported 
ones among the 248 participants. In particular, the highest 
reported comorbidities were hypertension (47.2%), diabetes 
(41.5%), dyslipidemia (38.7%), and benign prostatic hyper-
plasia (9.3%). Significant sex differences were observed 
Table 1 Demographic and clinical characteristics of the aged lebanese patients and prevalence of PIMs (n=248)
Variable N (%) Prevalence of  
PIMs
Association between PIMs  
use and variable: OR (95% CI)
Level of association 
significance: P-value
Age (years) [Mean ± sD] 70.9±5.0 112 (45.2%)a 1.08 (1.02, 1.14) 0.005*
Age group (years) [n (%)]
65–69 121 (48.8) 50 (41.3%) 0.24 (0.08, 0.69) 0.008*
70–74 77 (31.0) 33 (42.9%) 0.25 (0.08, 0.76) 0.014*
75–79 30 (12.1) 14 (46.7%) 0.29 (0.08, 1.01) 0.052
$80 20 (8.1) 15 (75.0%) 1
sex [n (%)] 0.086
Female 107 (43.1) 55 (51.4%) 1.56 (0.94, 2.59)
Male 141 (56.9) 57 (40.4%) 1
Cigarette smoking [n (%)] 0.219
Yes 74 (29.8) 29 (39.2%) 0.71 (0.41, 1.23)
no 174 (70.2) 83 (47.7%) 1
Alcohol consumption [n (%)] 0.049*
Yes 62 (25.0) 20 (32.3%) 0.52 (0.27, 0.99)
no 186 (75.0) 92 (49.5%) 1
Notes: a95% confidence interval is 39.0%–51.4%. *Significant at the 5% level.
Abbreviations: CI, confidence interval; OR, odds ratio; PIM, potentially inappropriate medication; SD, standard deviation.
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among few of the reported diseases, excluding benign pro-
static hyperplasia. As such, coronary artery disease/angina 
and benign prostatic hyperplasia were reported significantly 
higher among males than females, while osteoporosis, anxiety, 
and depression were significantly more prevalent among the 
female participants. Comorbidities are detailed in Table 2.
Primary outcome: medication 
appropriateness
Our study identified 112 (45.2%) out of 248 patients taking 
PIMs. Distribution of PIMs in our sample according to the 
Beers criteria of 2012 was as follows: 35.5% (n=88) cases 
were identified taking medications to be avoided in older adults. 
Additionally, 11.7% (n=29) cases were taking medications to be 
avoided in older adults with certain diseases and syndromes that 
the drugs can exacerbate, and 17.7% (n=44) cases were taking 
drugs to be used with caution in older adults (Table 3).
Classes of medications identified to cause 
PIMs
The classes of medications identified to cause PIMs involved 
141 drugs among aged Lebanese patients (Table 4). Drugs 
Table 2 Comorbidities of the aged patients (n=248)
Comorbidity Overall n (%) Males n (%) Females n (%)
Diseases of the circulatory system
hypertension 117 (47.2) 74 (52.5) 43 (40.2)
heart failure 8 (3.2) 6 (4.3) 2 (1.9)
Coronary artery diseases/angina* 16 (6.5) 13 (9.2) 3 (2.8)
Peripheral artery disease 7 (2.8) 2 (1.4) 5 (4.7)
Arrhythmia 7 (2.8) 3 (2.1) 4 (3.7)
Cardiovascular disease 3 (1.2) 1 (0.7) 2 (1.9)
endocrine, nutritional, and metabolic diseases
Diabetes 103 (41.5) 61 (43.3) 42 (39.3)
Dyslipidemia 96 (38.7) 58 (41.1) 38 (35.5)
Thyroid dysfunctions 5 (2.0) 1 (0.7) 4 (3.7)
Disease of the digestive system
Gastroesophageal reflux disease/ulcer 11 (4.4) 9 (6.4) 2 (1.9)
Constipation 6 (2.4) 2 (1.4) 4 (3.7)
Crohn’s disease 3 (1.2) 1 (0.7) 2 (1.9)
liver failure 1 (0.4) 0 (0.0) 1 (0.9)
Diseases of the musculoskeletal system and connective tissue
Osteoporosis* 20 (8.1) 1 (0.7) 19 (17.8)
Arthritis/back pain 5 (2.0) 1 (0.7) 4 (3.7)
Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified
Incontinence 4 (1.6) 1 (0.7) 3 (2.8)
Gastrointestinal pain/flatulence 2 (0.8) 2 (0.8) 0 (0.0)
Diseases of the genitourinary system
Benign prostatic hyperplasia* 23 (9.3) 23 (16.3) 0 (0.0)
renal failure 3 (1.2) 1 (0.7) 2 (1.9)
Diseases of the respiratory system
Asthma 11 (4.4) 5 (3.5) 6 (5.6)
Disease of the nervous system
Parkinson 14 (5.6) 10 (7.1) 4 (3.7)
seizures 6 (2.4) 2 (1.4) 4 (3.7)
Apnea 1 (0.4) 1 (0.7) 0 (0.0)
Mental and behavioral disorders
Alzheimer/dementia 17 (6.9) 9 (6.4) 8 (7.5)
Anxiety/depression* 8 (3.2) 1 (0.7) 7 (6.5)
Psychiatric problem (unspecified) 3 (1.2) 0 (0.0) 3 (2.8)
Diseases of the eye and adnexa
glaucoma 7 (2.8) 6 (4.3) 1 (0.9)
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
Coagulopathy 3 (1.2) 0 (0.0) 3 (2.8)
neoplasms
Cancer 2 (0.8) 0 (0.0) 2 (1.9)
Other diseases 19 (7.7) 10 (7.1) 9 (8.4)
Note: *Significant sex difference between males and females at P,0.05.
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After adjusting for all other variables in the model, 
patients who suffered from any of the three aforementioned 
diseases had increased odds of PIMs as compared with those 
who did not. In particular, a patient suffering from osteo-
porosis or Alzheimer/dementia has, respectively, 5.29 and 
3.21 times the odds of having inappropriate drug prescriptions 
as compared with an elder person free from these diseases. 
Still in the final model, patients who do not consume alcohol 
had ~1.92 times the odds of having PIMs as compared with 
those who consume alcohol. Finally, the risk of inappropriate 
drug prescriptions was significantly associated with age (odds 
ratio [OR] =1.08, 95% CI =1.02–1.14). “For every 5 years 
increase in age, the possibility of taking PIMs is multiplied 
by the OR raised to the power 5 (1.47; Table 5).”
Beers criteria of 2003 versus 2012
Out of the 112 patients who are taking PIMs, 45 patients were 
taking medications that have been added to Beers criteria of 
2012 and were therefore not included in the classification 
of 2003. The remaining 67 patients were taking at least one 
medication that was listed as inappropriate in the Beers 
criteria of 2003. The difference in the prevalence rates of 
PIMs use in Lebanon, as assessed by Beers criteria of 2003 
in Saab et al22 and criteria of 2012 in our study, was tested 
twice taking into account or not those 45 patients taking the 
recently listed medications.
First, when comparing the prevalence of PIMs in Lebanon 
based on both Beers criteria of 2003 and 2012, the overall 
prevalence of 45.2% of patients with PIMs use in our study is 
Table 3 Prevalence drugs according to Beers criteria of 2012 in 
the lebanese patients (n=248)
Drugs n (%)
Appropriate drug use 136/248 (54.8)
PIMs 112/248 (45.2)
PIMs and classes to avoid in older adults 88/248 (35.5)a
PIMs and classes to avoid in older adults with certain 
diseases and syndromes that the drugs can exacerbate
29/248 (11.7)a
PIMs to be used with caution in older adults 44/248 (17.7)a
Note: anumbers do not add to 112 as patients might have multiple categories of PIMs.
Abbreviation: PIMs, potentially inappropriate medications.
acting on the central nervous system were the leading ones 
(71.4%), followed by those of the circulatory system (13.5%). 
Antidiabetic agents accounted for 13.1% of the total PIMs.
Correlates of the PIMs
The main outcome was the PIM use as per Beers criteria of 
2012 at the bivariable and multivariable levels. Using the 
bivariate analysis, there were no associations between this 
main outcome and age, cigarette smoking, or alcohol use. 
However, females had 2.66 times the odds of having inap-
propriate drug prescriptions as compared with males.
The Hosmer and Lemeshow goodness-of-fit test produced 
a P-value of 0.11, suggesting the multivariable logistic model 
fits the data. The final model included sex, alcohol consump-
tion, and age as predictive factors along with osteoporosis, 
Alzheimer/dementia, and diabetes.
Table 4 Classes of medications identified to cause PIMs in aged 
lebanese patients (n=141)
Organ system or therapeutic category or drug n (%)
Circulatory system
Aldosterone receptor antagonist 1 (0.7)
Antiarrhythmic drugs (Class Ia) 1 (0.7)
Aspirin 9 (6.4)
nondihydropyridine calcium channel blockers 8 (5.7)
endocrine system
Insulin 3 (2.1)
Oral antidiabetic drugs 15 (11.0)
Central nervous system
Anticholinergics 3 (2.1)
Anticonvulsants 15 (11.0)
Antipsychotics 6 (4.3)
Benzodiazepines 41 (29.0)
sedative/hypnotics 19 (13.0)
selective serotonin reuptake inhibitors 8 (5.7)
serotonin norepinephrine reuptake 5 (3.5)
Tricyclic antidepressants 4 (2.8)
Miscellaneous
Prokinetics 1 (0.7)
h1 and h2 antihistamines 2 (1.4)
Abbreviation: PIMs, potentially inappropriate medications.
Table 5 Multivariable logistic regression: dependent variable is 
PIMs use
Variable OR (95% CI) P-value
Osteoporosis 0.006*
Yes 5.29 (1.60, 17.51)
no 1
Alzheimer/dementia 0.042*
Yes 3.21 (1.05, 9.85)
no 1
Diabetes 0.004*
Yes 2.25 (1.29, 3.92)
no 1
Alcohol consumption 0.049*
Yes 0.52 (0.27, 0.99)
no 1
sex 0.409
Female 1.27 (0.72, 2.26)
Male 1
Age (in years) 1.080 (1.02, 1.14) 0.008*
Note: *Significant at the 5% level.
Abbreviations: CI, confidence interval; OR, odds ratio; PIMs, potentially inappro­
priate medications.
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significantly higher than the prevalence in Saab et al (45.2% 
versus 22.4%, respectively, P,0.001). Second, the preva-
lence of PIMs use in Lebanon did not increase significantly 
when comparing the prevalence of PIMs across years using 
the same Beers criteria of 2003 (P=0.218). Finally, using 
Beers criteria of 2012 yielded a significantly higher PIMs 
use within our sample as compared with the 2003 criteria 
(45.2% versus 27%, respectively, P,0.001; Table 6). Our 
findings suggest that the significant difference between the 
two studies is due to the new list of medications to be avoided 
in addition to drug classes to be used with caution in aged 
that were absent in Beers criteria of 2003 but were included 
in the updates of Beers criteria of 2012.
Discussion
PIMs in lebanon
High prevalence of PIMs use was identified among aged 
in Lebanon as per the final updated 2012 Beers criteria 
(45.2%). To our knowledge, this is the first study to assess 
PIMs use with Beers Criteria of 2012 in Lebanon. However, 
one study in 2005 has investigated the prevalence of PIMs 
among aged outpatients in Lebanon in terms of Beers criteria 
of 2003 (22.4%).22
Comparison with international studies
The prevalence of PIMs in this study was apparently higher 
than that found in studies conducted in other countries, 
where the 2003 version of the Beers criteria was adopted to 
evaluate the prescriptions (13%–40.7%).4,20,24–26 However, our 
results fall in the same range as those reported by the New-
Zealander and Brazilian studies which based their analysis on 
the 2012 Beers criteria.14,16 Nishtala et al studied the database 
of a cohort of community-dwelling older people in New 
Zealand and found that the prevalence of PIMs among aged 
outpatients according to Beers criteria of 2012 was 42.7%.14 
The Brazilian cross-sectional study found a prevalence of 
59.2% in PIMs use among pharmacy outpatients.16 Those 
high rates of PIMs use might be related to the high rate of 
self-medication.14,16 Official data about auto-medication are 
lacking in Lebanon. Moreover, the prevalence in different 
populations may vary according to the time and place of 
data gathering.13 As such, factors like ethnicity, economic 
incomes, and duration of data gathering may also contribute 
toward the differences.27,28
Alongside studies about PIMs use among aged outpa-
tients, others detected a high prevalence of PIMs use in 
hospitalized aged and recipients of home health care services 
in Nigeria, Taiwan, and India, according to Beers criteria of 
2012.17,29,30 One feature of the Indian study is that it explained 
the reason of the increasing rate of PIMs use when comparing 
the Beers criteria of 2003 and 2012. This point will be further 
discussed throughout the following sections.
Classes of medications identified to cause 
PIMs
We observed a predominance of inappropriate medications 
acting on the central nervous system (71.4%). Similar find-
ings were observed in studies conducted among residents of 
long-term care for the aged.19,31,32 The predominant use of 
benzodiazepines, sedative, and hypnotics among our study 
population reflects the high number of older adults affected by 
mental disorders such as depression, anxiety, and insomnia, 
as reported by Converso and Iartelli33 and Lenardt et al.34
Correlates of the PIMs
We found that age and certain comorbidities (osteoporosis, 
diabetes, and Alzheimer/dementia) were associated with the 
use of PIMs. A unique finding in our study is that taking PIMs’ 
odds is multiplied by the OR to the power 5, for every 5 years 
increase in age. Moreover, the relationship between PIMs use 
and alcohol consumption was barely significant (P=0.049). 
Older patients are more likely than younger ones to receive 
medical prescriptions and may therefore be more likely to 
abstain from alcohol to avoid interactions. Consequently, 
because polymedicated older patients generally may drink 
less than younger ones and are more likely at risk of taking 
PIMs,35 our study findings may be less likely to recognize 
alcohol consumption as a risk factor.
Table 6 Prevalence of PIMs use in lebanon as described by Beers criteria of 2003 versus 2012
Present study n (%) Saab et al22 n (%) P-value
Comparing the prevalence of PIMs across years using different Beers criteria 112/248 (45.2)a 62/277 (22.4)b ,0.001*,c
Comparing the prevalence of PIMs across years using same Beers criteria (2003) 67/248 (27.0)b 62/277 (22.4)b 0.218c
Comparing patients within the present study using the two criteria 112/248 (45.2)a 67/248 (27.0)b ,0.001*,d
Notes: aBased on 2012 Beers Criteria. bBased on 2003 Beers Criteria. cBased on the chi-squared test. dBased on McNemar’s test. *Significant at the 5% level.
Abbreviation: PIMs, potentially inappropriate medications.
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The majority of aged patients have multiple comorbidi-
ties, including osteoporosis, which in turn lead to a greater 
consumption of medications and increase the likelihood of 
receiving a prescription that includes one or more inappro-
priate medications.19,36 Furthermore, elderly patients with 
diabetes are particularly vulnerable because of the additive 
deleterious effects of diabetes on cognitive functions. Studies 
have shown that patients with diabetes were noted to have 
impaired memory and attention.37–41 Degenerative disorders 
of the brain such as Alzheimer’s disease and dementia lead 
to gait disturbances, confusion and memory loss impeding 
their ability to comply with the medication precautions.42,43 
Finally, according to Wawruch et al44 the association between 
PIMs use and certain pathologies could be an important 
marker of incorrect disease management and a tendency 
for inappropriate prescriptions. This finding shows the 
importance of understanding what conditions or factors are 
associated with inappropriate medication use, as having this 
knowledge makes it possible to evaluate the quality of the 
health care provided.
Beers criteria of 2003 versus 2012
Our results showed that PIMs use increased significantly 
in Lebanon between Beers criteria of 2003 as identified 
by Saab et al in 200622 and 2012 (P,0.001, Table 6). 
Similar conclusions are found in the literature.16,30 Due to 
the continuous addition of medications to the market, the 
American Geriatrics Society updated in 2012 the Beers 
criteria by using an evidence-based approach.10 As in the 
past, this update categorized PIMs into two broad groups: 
medications to avoid in older adults regardless of diseases 
or conditions and medications considered potentially inap-
propriate when used in older adults with certain diseases 
or syndromes. A third group of medications that should 
be used with caution, was added. The latest version of the 
PIMs list in the 2012 guidelines has been updated with the 
addition of new drugs and the omission of drugs that are 
no longer used or available on the market. Beers criteria of 
2012 are hence found to be stricter than Beers criteria of 
2003 in identifying the PIMs use. This may be attributed to 
the significant changes made in the updated Beers criteria, 
mainly the addition of the third category of PIMs, and a 
new set of medications that are considered as inappropri-
ate since 2003.
In parallel, regardless of which set of Beers criteria is 
used, the increase of prevalence from 22.4% in 200622 to 
27% in the current study is not significant. Nonetheless, this 
is contradictory with the findings of Zimmermann et al.45 
The latter revealed that the use of PIMs according to Beers’ 
list significantly decreased from 21% to 17.1% over a period 
of 4.5 years in a cohort of German patients aged $75 years 
because of a more rational drug therapy. Even though aware-
ness to PIMs has been increasing, our results underlines the 
unfortunate fact that patients in the Lebanese community 
can acquire most prescription medications, excluding 
psychotropic drugs, narcotics, cocaine, and other highly 
addictive substances, without a physician’s prescription. 
This is mainly due to the absence of law application and 
reinforcement.
Finally, given the relevance of the inappropriate use 
of drugs, and since medications that are widely used 
should now be avoided or used with caution as per Beers 
criteria of 2012, health care providers are urged to take 
the necessary precautions when managing these medica-
tions in aged population. As such, a Swedish study found 
that the extent of inappropriate drug prescriptions for 
the aged ($65 years of age) improved over the period 
2006–2013 due to improved/safer prescribing practices 
adopted by physicians when dealing with elderly patients.46 
Additionally, pharmacists play a major role in reducing 
suboptimal prescribing as disclosed in a review that evalu-
ated the impact of pharmacists’ interventions to improve 
the appropriateness of prescribing in the aged.47 Lastly, 
regardless of which Beers criteria are adopted, there is a 
high prevalence of PIMs use in Lebanese aged outpatients, 
which must be brought to the attention of clinicians. In 
this context, a debate on drug therapy for the aged must 
be initiated to encourage prescribers to periodically review 
all medications in relation to the Beers criteria and to be 
alerted about new medicines as guidance to good geriatric 
care and medication safety practices.
study limitations
Two limitations of this survey should be noted. First, the 
results of our study cannot be generalized to the aged patients 
across Lebanon, including institutionalized aged people 
in nursing homes or care centers, because this study was 
restricted to the prescription profile of outpatients in com-
munity pharmacies. Second, the convenience sampling may 
have underestimated the prevalence of PIMs. The rationale 
is that many patients get their medications from dispensa-
ries where only generic drugs can be dispensed based on a 
prescription with or without the presence of a pharmacist, 
which can increase the risk of inappropriateness.
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Conclusion
This study is the first Lebanese study to evaluate the use of 
PIMs in the aged using the revised Beers criteria of 2012.10 
It identified age, osteoporosis, diabetes, and Alzheimer/
dementia as risk factors and alcohol consumption as a 
protective one for the use of PIMs in Lebanon. Besides, the 
prevalence of PIMs was found to be relatively high in Leba-
nese outpatient older people. Importantly, our study showed 
that the prevalence of PIMs increased significantly from 
22.4% to 45.2% across years using Beers criteria of 2003 
and 2012, mainly because of the change of set of criteria. 
Nonetheless, the increase of prevalence from 22.4% in 2003 
to 27% in the current study is not significant when using the 
same Beers criteria of 2003. Therefore, PIMs defined by the 
Beers criteria of 2012 might be a useful initial screening 
tool, before efforts to stop unsafe medication use or replace 
with safer alternatives are initiated. It is also imperative 
that health care professionals raise their awareness about 
inappropriate pharmacotherapy with a goal to prevent and 
mitigate complications. Thus, part of the pharmacists’ role 
is to perform medication therapy management which con-
sists of making recommendations about drug selection and 
modification. Consequently, improving medical prescribing 
and decreasing the prevalence of PIMs in Lebanon.
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